NAMS vs SUPN: stock comparison and AI forecast
Newamsterdam Pharma Co N.V. (NAMS) and Supernus Pharmaceuticals, Inc. (SUPN) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
NAMS Newamsterdam Pharma Co N.V.
- Price
- $19.56 -34.5% · 6M
- Market Cap
- $2.34B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
SUPN Supernus Pharmaceuticals, Inc.
- Market Cap
- $2.44B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- NAMS and SUPN have similar market capitalizations ($2.34B and $2.44B).
- SUPN turns -5.1% of its revenue into net income, against -2569.6% for NAMS.
- SUPN carries 0.32 times debt per unit of equity, against 0.12 times for NAMS.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | NAMS | SUPN |
|---|---|---|
| Market Cap | $2.34B | $2.44B |
| P/B Ratio | 3.70x | 2.29x |
| EPS | $-2.09 | $-0.54 |
| Book Value/Share | $5.28 | $18.28 |
| Revenue/Share | $0.08 | $14.88 |
| FCF/Share | $-1.20 | $1.50 |
Profitability & Margins
| Metric | NAMS | SUPN |
|---|---|---|
| ROE | -41.1% | -4.1% |
| ROA | -36.8% | -3.1% |
| ROIC | -38.7% | -4.4% |
| Gross Margin | – | 87.6% |
| Operating Margin | -2420.1% | -5.7% |
| Net Margin | -2569.6% | -5.1% |
| EBT Margin | -2569.6% | -5.0% |
| Tax Rate | – | -2.9% |
Financial Health
| Metric | NAMS | SUPN |
|---|---|---|
| Current Ratio | 9.03x | 2.49x |
| Quick Ratio | – | 2.10x |
| D/E Ratio | 0.12x | 0.32x |
| Financial Leverage | 1.12x | 1.32x |
| Interest Coverage | – | -19.3x |
| Working Capital | $586M | $426M |
Cash Flow
| Metric | NAMS | SUPN |
|---|---|---|
| Operating Cash Flow | -$143M | $88M |
| Free Cash Flow | -$144M | $87M |
| Capital Spending | -$260K | -$1M |
| OCF Growth YoY | – | 22.7% |
| FCF Growth YoY | – | 22.9% |
| FCF/Sales | -1423.1% | 10.1% |
| CapEx/Sales | 2.6% | 0.1% |
Operational Efficiency
| Metric | NAMS | SUPN |
|---|---|---|
| Asset Turnover | 0.01x | 0.62x |
| Receivables Turnover | – | 4.0x |
| Inventory Turnover | – | 0.9x |
| Fixed Assets Turnover | 24.6x | 86.3x |
| Days Sales Outstanding | – | 91 days |
| Days Inventory | – | 386 days |
| Payables Period | – | 29 days |
| Cash Conversion Cycle | – | 448 days |
Income Statement
| Metric | NAMS | SUPN |
|---|---|---|
| Total Revenue | $10M | $865M |
| Operating Income | -$244M | -$49M |
| Net Income | -$260M | -$44M |
| R&D Expense | $149M | $122M |
| SG&A Expense | $102M | $509M |
| Cost of Goods Sold | – | $107M |
Dividend & Shareholder Information
| Metric | NAMS | SUPN |
|---|---|---|
| Shares Outstanding | 120M | 58M |
NAMS vs SUPN: stock comparison and AI forecast
Which is bigger, NAMS or SUPN?
NAMS and SUPN have similar market capitalizations ($2.34B and $2.44B).
Which one does Intratio's AI model rank higher, NAMS or SUPN?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.